NL-OMON46635撤回2 期
A randomized, double-blind, placebo-controlled parallel arm dose titration study to assess the effects of SAR407899 in patients with microvascular angina and/or persistent stable angina despite angiographically successful percutaneous coronary intervention (PCI) - ACT14656
适应症
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •- Male or female patient not at childbearing potential *18 year-old or legal age of majority.;- Female patient if she has undergone sterilization at least 3 months earlier or is postmenopausal.;- Post-menopausal status is defined by having no menses for 12 months without an alternative medical cause.;- In females not treated with hormonal replacement therapy (HRT), menopausal status is confirmed by a high follicle stimulating hormone (FSH) level greater than 40 IU/L.;- In females on HRT and whose menopausal status is in doubt (ie, in women aged less than 45 years), a highly effective contraception methods will be required. Contraception should be used during the whole study and for at least seven days corresponding to time needed to eliminate study treatment.;- Symptomatic stable angina pectoris (typical or atypical symptoms with an average of at least biweekly episodes over the past month),;- Electrocardiogram (ECG) evidence of ischemia with ;ST-segment depression during a symptom limited exercise test or non-invasive evidence of ischemia [echo, single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), positron emission tomography (PET)] within previous 12 months.;- Patients with *normal* or *subnormal* (<50% stenosis) coronary arteries or intermediate stenosis (between 50 and 70%) should have fractional flow reserve (FFR) >0.80 on angiogram documented within the previous 12 months. In patients with stenting, a minimum diameter stenosis of <10% is required.;or;Coronary computed tomography angiography (CCTA) without regional abnormal perfusion defects within 12 months in patients without previous PCI.
- •Or CCTA performed during screening period, with finding of non-obstructive coronary arteries, in patients diagnosed with MVA and stable angina without previous PCI who did not have a coronary angiogram or CCTA in the previous 24 months but between 24 months to 5 years. ;- Baseline global CFR (measured during the study) assessed by 13N-ammonia or 82rubidium PET scan <2.0.
排除标准
- •- Esophageal dysmotility or esophagitis.;- Any use of long-acting nitrates and/or calcium channel blockers (CCBs) and/or phosphodiesterase type 5 (PDE5) inhibitors within one week prior to baseline PET scan or anticipated to be used during the study.;- Patients with acute coronary syndrome (ACS) [myocardial infarction (MI) and/or unstable angina] in previous 3 months.;- Unsuccessful or incomplete coronary revascularization with residual obstructive stenosis or coronary artery disease (CAD) progression in native vessels as documented on invasive coronary angiography (*50% stenosis) within 12 months of enrollment.;- Patients with history of coronary artery bypass grafting (CABG).;- Percutaneous coronary intervention performed at the time of an ACS (MI or unstable angina) in the previous 12 months.;- Recent elective PCI within the past 3 months.;- Contraindication to vasodilator stress PET scan and or CCTA if CCTA needed during screening.;- Regional local flow abnormal perfusion defects at baseline PET scan.;- Recent (*3 months) major surgery (ie, valvular surgery, surgery for congenital heart disease), stroke, transient ischemic attack (TIA), sustained ventricular arrhythmia, clinically significant structural heart disease (moderate-severe valvular disease, hypertrophic cardiomyopathy, congenital heart disease, pulmonary hypertension).;- Patients with cardiac conduction abnormalities (second or third degree atrioventricular [AV] block, sick sinus syndrome, symptomatic bradycardia, sinus node disease). Except in patients fitted with a functioning pacemaker.;- History or known carotid stenosis:
- •- carotid stenosis (>50%) or
- •- history of carotid stenosis in patient with previous symptoms;- Contraindication or known hypersensitivity to adenosine (or regadenoson).;- Contraindication to aminophylline.;- Ongoing dipyridamole treatment.;- Inability to discontinue treatment with methylxanthines treatment within 24 hours prior to PET scan.;- Patient unable to read, understand and fill a questionnaire without any help (eg, partially visually impaired or blind).;- Systolic Blood Pressure (SBP) <120 mmHg at baseline.;- Presence at baseline of symptomatic orthostatic hypotension (SBP decrease of 20 mmHg or more at Minute 3 and Minute 5 between seated and standing position), or asymptomatic orthostatic hypotension with a decrease in SBP equal or greater than 30 mmHg at Minute 3 and Minute 5 when changing from the seated to the standing position.;- Renal impairment [estimated glomerular filtration rate (eGFR) <50 milliliter (mL)/min/1.73m2 at screening and baseline].;- Drug-induced liver injury related criteria: ;- Underlying hepatobiliary disease, ;- ALT >3 times the upper limit of normal (ULN).
研究者
相似试验
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, parallel group trial of HMR1766 assessing the efficacy and safety of 3 doses of HMR1766 (25, 100, 200 mg OD) versus placebo with cilostazol, 100 mg BID as a calibrator, administered for 26 weeks in patients with Peripheral Arterial Disease (PAD) Fontaine stage II. - ACCELAPeripheral Arterial Disease (PAD) Fontaine stage II (intermittent claudication)MedDRA version: 8.1Level: LLTClassification code 10022562Term: Intermittent claudicationEUCTR2006-004275-35-FRsanofi-aventis recherche & développement550
进行中（未招募）
不适用
A study to determine the appropriate dose(s) of Dupilumab (REGN668)in adult patients with moderate to severe atopic dermatitis (eczema)Atopic dermatitsMedDRA version: 16.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2012-003651-11-PLRegeneron Pharmaceuticals, Inc.240
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group trial of HMR1766 assessing the efficacy and safety of 3 doses of HMR1766 (25, 100, 200 mg OD) versus placebo with cilostazol, 100 mg BID as a calibrator, administered for 26 weeks in patients with Peripheral Arterial Disease (PAD) Fontaine stage II. - ACCELAPeripheral Arterial Disease (PAD) Fontaine stage II (intermittent claudication)MedDRA version: 8.1Level: LLTClassification code 10022562Term: Intermittent claudicationEUCTR2006-004275-35-ATsanofi-aventis recherche & développement550
进行中（未招募）
1 期
Efficacy and safety of dexketoprofen trometamol and tramadol hydrochloride combination on moderate to severe acute pain in patients with acute low back paiow back painMedDRA version: 21.0Level: LLTClassification code 10024891Term: Low back painSystem Organ Class: 100000004859EUCTR2019-003656-37-ESMenarini International Operations Luxembourg SA538
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with traditional DMARD therapy in patients with moderate to severe active rheumatoid arthritis and an inadequate response to current DMARD therapy.Rheumatoid ArthritisEUCTR2004-005210-37-DEF. Hoffmann La-Roche AG1,200